- Home
- ANIX vs SGMT Comparison
ANIX vs SGMT Comparison
Compare ANIX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- SGMT
- Stock Information
- Founded
- ANIX 1982
- SGMT 2006
- Country
- ANIX United States
- SGMT United States
- Employees
- ANIX N/A
- SGMT N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- SGMT
- Sector
- ANIX Health Care
- SGMT
- Exchange
- ANIX Nasdaq
- SGMT Nasdaq
- Market Cap
- ANIX 101.4M
- SGMT 93.7M
- IPO Year
- ANIX 1987
- SGMT 2023
- Fundamental
- Price
- ANIX $3.08
- SGMT $4.73
- Analyst Decision
- ANIX Strong Buy
- SGMT Strong Buy
- Analyst Count
- ANIX 2
- SGMT 5
- Target Price
- ANIX $8.50
- SGMT $21.60
- AVG Volume (30 Days)
- ANIX 128.3K
- SGMT 792.4K
- Earning Date
- ANIX 01-14-2025
- SGMT 11-13-2024
- Dividend Yield
- ANIX N/A
- SGMT N/A
- EPS Growth
- ANIX N/A
- SGMT N/A
- EPS
- ANIX N/A
- SGMT N/A
- Revenue
- ANIX N/A
- SGMT N/A
- Revenue This Year
- ANIX N/A
- SGMT N/A
- Revenue Next Year
- ANIX N/A
- SGMT N/A
- P/E Ratio
- ANIX N/A
- SGMT N/A
- Revenue Growth
- ANIX N/A
- SGMT N/A
- 52 Week Low
- ANIX $2.15
- SGMT $2.31
- 52 Week High
- ANIX $5.13
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- ANIX 42.34
- SGMT 41.81
- Support Level
- ANIX $3.07
- SGMT $5.61
- Resistance Level
- ANIX $4.20
- SGMT $6.40
- Average True Range (ATR)
- ANIX 0.30
- SGMT 0.53
- MACD
- ANIX -0.06
- SGMT -0.16
- Stochastic Oscillator
- ANIX 2.61
- SGMT 8.24
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).